Clinical trials: Synucleinopathies
Parkinson Disease
Intranasal Insulin in Parkinson's Disease
This project will investigate exploratory outcomes related to the effect of intranasal insulin on cognition, mood, apathy and motor performance of subjects with Parkinson's disease over a 3 week period.
- Trial name
- INI-PD (NCT04251585)
- Testing
- Regular Novolin R
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- HealthPartners Institute
Parkinson's Disease, Deep Brain Stimulation Surgery
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
The purpose of this research study is to find out whether dexmedetomidine changes brain cell activity in the subthalamic nucleus (STN).
- Trial name
- NCT01721460
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
Parkinson's Disease
Deep Brain Stimulation Effects on Gait and Balance in Patients With Parkinson's Disease
The purpose of this study is to evaluate the effect of Deep Brain stimulation (DBS) on walking in patients with Parkinson's disease that have had DBS.
- Trial name
- NCT02022735
- Testing
- Deep Brain Stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Parkinson Disease
Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease
The objective of this study is to further the understanding and application of 60Hz subthalamic deep brain stimulation (STN-DBS) in Parkinson's patients with gait disorder.
- Trial name
- NCT04184791
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwell Health
Dementia With Lewy Bodies
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
- Trial name
- COG1201 (NCT05225415)
- Testing
- CT1812
- Where
- 34 sites in United States
- Volunteers
- 130 people
- Sponsor
- Cognition Therapeutics
Parkinson's Disease
Vibrotactile Stimulation in Parkinson's Disease
The purpose of this study is to examine the possibility of a new, non-invasive, non-drug treatment for Parkinson's disease. The treatment involves gentle vibratory stimulation delivered to the fingertips (called 'vibrotactile…
- Trial name
- NCT02933476
- Testing
- Vibrotactile Stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Healthy Volunteers
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or…
- Trial name
- NCT06088784
- Testing
- ATH-399A, ATH-399A 10 mg, 5 mg ATH-399A capsule
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Parkinson Disease
Safety of Urate Elevation in Parkinson's Disease
The purpose of this study is to determine the safety and tolerability of inosine and its ability to raise urate levels in blood and cerebral spinal fluid in individuals with early Parkinson disease.
- Trial name
- SURE-PD (NCT00833690)
- Testing
- inosine
- Where
- 16 sites in United States
- Volunteers
- 75 people
- Sponsor
- The Parkinson Study Group
Multiple System Atrophy, MSA
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
- Trial name
- NCT02388295
- Testing
- AZD3241
- Where
- 17 sites in United States, Austria and 5 more
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Frontotemporal Dementia, Dementia
Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE)
The protocol is organized into three Phases - In Phase I an online training program will be developed in "Care of Persons with Dementia in their Environments" (COPE) -an evidence-based bio-behavioral dementia program -using…
- Conditions
- Frontotemporal Dementia, Dementia, Multi-Infarct Dementia, Vascular Dementia
- Trial name
- NCT04165213
- Testing
- Care of Older Persons in their Environment (COPE) online module training
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Anxiety Disorders, Parkinson Disease
Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment
This study will evaluate the effectiveness of the rotigotine transdermal patch in reducing anxiety in people with Parkinson's disease.
- Trial name
- ANXPD (NCT02365870)
- Testing
- rotigotine transdermal patch
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Johns Hopkins University
Parkinson's Disease
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study
To evaluate DBS device settings and match with the features of the DBS care management software.
- Trial name
- DBS (NCT01750242)
- Testing
- Medtronic DBS system
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- MedtronicNeuro
Parkinson Disease
Efficacy of Isradipine in Early Parkinson Disease
The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.
- Trial name
- NCT02168842
- Testing
- Isradipine
- Where
- 54 sites in United States, Canada
- Volunteers
- 336 people
- Sponsor
- University of Rochester
Medication-Induced Dyskinesia
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA…
- Trial name
- NCT05148884
- Testing
- NLX-112
- Where
- 5 sites in Sweden
- Volunteers
- 27 people
- Sponsor
- Neurolixis SAS
Parkinson's Disease
A Study to Examine APL-130277 in Patients With Parkinson's Disease
The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)
- Trial name
- NCT02228590
- Testing
- APL-130277
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sumitomo Pharma America, Inc.
Parkinson Disease
A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.
- Trial name
- NCT04435431
- Testing
- Mesdopetam
- Where
- 44 sites in United States, France and 4 more
- Volunteers
- 155 people
- Sponsor
- Integrative Research Laboratories AB
Parkinson Disease, Tremor
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual…
- Trial name
- NCT05642442
- Testing
- Suvecaltamide
- Where
- 37 sites in United States, Germany and 2 more
- Volunteers
- 169 people
- Sponsor
- Jazz Pharmaceuticals
Parkinson Disease
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD.
- Trial name
- NCT03582137
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Colorado, Denver
Parkinson's Disease
High and Low Dose Carbidopa Treatment of Parkinson's Disease
Hypothesis: We hypothesize that carbidopa in daily doses of 450mg will enter the central nervous system and partially inhibit AAAD, thereby reducing the decarboxylation of exogenous levodopa to dopamine, and thereby blunt the…
- Trial name
- NCT01399905
- Testing
- carbidopa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Oregon Health and Science University
Parkinson's Disease
Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)
An extension study for subjects with prior participation in previous resonator studies using low level magnetic fields to treat some of the symptoms of idiopathic Parkinson's Disease.
- Trial name
- NCT00862537
- Testing
- Resonator Device
- Volunteers
- 18 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC